• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

    10/1/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CCCC alert in real time by email

    WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial.

    The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with multiple myeloma. This Phase 1b trial, which is expected to initiate in Q2 2026, will seek to establish an optimal dose for cemsidomide in combination with elranatamab. Under the terms of the agreement, Pfizer will supply elranatamab at no cost while C4T will sponsor and conduct the trial.

    "We look forward to initiating this trial to evaluate cemsidomide in combination with elranatamab in the hopes we can develop a new treatment regimen and potentially improve outcomes for multiple myeloma patients in earlier lines of therapy," said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. "Our supply agreement with Pfizer creates an opportunity for cemsidomide to be combined with elranatamab, which is on the path to potentially becoming a standard of care BCMAxCD3 bispecific in a growing market."

    Data generated from the cemsidomide Phase 1 trial in relapsed/refractory multiple myeloma demonstrate robust T-cell activation and cytokine expression across multiple doses. By activating immune T-cells, cemsidomide, when combined with a BCMAxCD3 bispecific such as elranatamab, may amplify the anti-myeloma immune response and lead to higher quality of responses.

    About C4 Therapeutics

    C4 Therapeutics (C4T) (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

    About Cemsidomide

    Cemsidomide is an investigational, orally bioavailable small-molecule degrader in clinical development for the treatment of relapsed/refractory multiple myeloma. Data from the Phase 1 trial, which has completed enrollment, demonstrate cemsidomide's differentiated safety and tolerability profile and class-leading anti-myeloma activity that together support the potential for durable outcomes. Two clinical trials are planned to further evaluate cemsidomide in relapsed/refractory multiple myeloma: a Phase 2 single-arm registrational trial to evaluate cemsidomide in combination with dexamethasone, which is expected to initiate in Q1 2026; and a Phase 1b trial to evaluate the safety and tolerability of cemsidomide and dexamethasone in combination with elranatamab, which is expected to initiate in Q2 2026.

    Forward-Looking Statements

    This press release contains "forward-looking statements" of C4 Therapeutics, Inc., within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement or cohort initiation; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; the potential timing for updates on our clinical and research programs; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in C4 Therapeutics' most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release and C4 Therapeutics undertakes no duty to update this information unless required by law.

    Contacts:

    Investors:

    Courtney Solberg

    Associate Director, Investor Relations

    [email protected]

    Media:

    Loraine Spreen

    Senior Director, Corporate Communications & Patient Advocacy

    [email protected]



    Primary Logo

    Get the next $CCCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCCC

    DatePrice TargetRatingAnalyst
    9/17/2025$8.00Overweight
    Barclays
    9/15/2025$6.00Equal-Weight → Overweight
    Stephens
    9/4/2025$8.00Buy
    Guggenheim
    12/19/2024$8.00 → $12.00Equal Weight → Overweight
    Wells Fargo
    11/18/2024$4.00Equal-Weight
    Stephens
    1/29/2024$6.00Underweight → Neutral
    JP Morgan
    12/13/2023$2.00 → $12.00Hold → Buy
    Stifel
    2/24/2023$12.00 → $10.00Underperform → Neutral
    Credit Suisse
    More analyst ratings

    $CCCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

    WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial. The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for

    10/1/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

    Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations Related to Cemsidomide and Few Dose Reductions Support a Safety Profile That May Be Ideal for Combination Regimens C4T to Pursue Differentiated Development Strategy With Two Distinct Opportunities for Accelerated Approval in Second Line and Later C4T to Host Webc

    9/20/25 11:00:20 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development timelines for life-saving cancer treatments[1], while major pharmaceutical companies deployed several multi-billion-dollar strategic partnerhips (with one topping $11 billion) to secure next-generation immunotherapies[2]. These recent designations are creating momentum for companies advancing breakthrough oncology platforms including Oncolytics Biotech Inc. (NASDAQ:ONCY), HUTCHMED (China) Limited (NASDAQ:HCM), CG Oncology, Inc. (NASDAQ

    9/8/25 9:30:00 AM ET
    $CCCC
    $CGON
    $HCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CCCC
    SEC Filings

    View All

    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Barclays initiated coverage on C4 Therapeutics with a new price target

    Barclays initiated coverage of C4 Therapeutics with a rating of Overweight and set a new price target of $8.00

    9/17/25 8:06:28 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics upgraded by Stephens with a new price target

    Stephens upgraded C4 Therapeutics from Equal-Weight to Overweight and set a new price target of $6.00

    9/15/25 8:00:09 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on C4 Therapeutics with a new price target

    Guggenheim initiated coverage of C4 Therapeutics with a rating of Buy and set a new price target of $8.00

    9/4/25 9:00:20 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - C4 Therapeutics, Inc. (0001662579) (Filer)

    10/1/25 7:06:28 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - C4 Therapeutics, Inc. (0001662579) (Filer)

    9/22/25 6:41:16 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.

    SCHEDULE 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    8/7/25 12:50:20 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Anderson Kenneth Carl was granted 5,349 shares, increasing direct ownership by 4% to 140,574 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    10/3/25 4:14:17 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Grogan Donna Roy was granted 6,740 shares, increasing direct ownership by 13% to 58,629 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    10/3/25 4:13:58 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Adams Kendra converted options into 6,250 shares and covered exercise/tax liability with 2,775 shares, increasing direct ownership by 2% to 162,342 units (SEC Form 4)

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    9/19/25 4:13:49 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Leadership Updates

    Live Leadership Updates

    View All

    C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

    Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations Related to Cemsidomide and Few Dose Reductions Support a Safety Profile That May Be Ideal for Combination Regimens C4T to Pursue Differentiated Development Strategy With Two Distinct Opportunities for Accelerated Approval in Second Line and Later C4T to Host Webc

    9/20/25 11:00:20 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

    WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada. IMS Annual Meeting 2025 Oral PresentationTitle: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaPresen

    9/3/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

    Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended

    2/27/25 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by C4 Therapeutics Inc.

    SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 6:43:36 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 4:05:17 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CCCC
    Financials

    Live finance-specific insights

    View All

    C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

    – Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies – – CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relative to Approved and Investigational IKZF1/3 Degraders – – On-Target Dose Limiting Toxicity Observed; Modeling Suggests Differentiated Activity and PK Profile Provides Pathway to Increase Therapeutic Index with Alternative Dosing Schedule – – Company to Host Conference Call and Webcast Today at 2 pm ET – WATERTOWN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical co

    4/8/22 1:00:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

    - Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation – - New Pre-clinical Data from CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted as Oral Presentations – - Conference Call and Webcast Scheduled for April 8, 2022, at 2 PM ET– WATERTOWN, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will pr

    3/8/22 4:30:00 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care